Wen Zhang

Wen Zhang

Auto-generated profile, based on publicly available information

Wen Zhang

Department of Burns, Tongren Hospital of Wuhan University (Wuhan Third Hospital) School of Pharmaceutical Sciences Wuhan University Wuhan People's Republic of China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 November 2022 in Endocrine Reviews
Verified
Journal Article
Open access
PDF file
HLHanqing Liu
Hanqing Liu
WLWei Li
Wei Li
WZWen Zhang
Wen Zhang
SSShengrong Sun
Shengrong Sun
CCChuang Chen
Chuang Chen
Although levothyroxine is one of the most prescribed medications in the world, its bioavailability has been reported to be impaired by many factors, including interfering drugs or foods and concomitant diseases, and persistent hypothyroidism with a high dose of levothyroxine is thus elicited. Persistent hypothyroidism can also be induced by noninterchangeability between formulations and poor compliance. To address these issues some strategies have been developed. Novel formulations (liquid solutions and soft gel capsules) have been designed to eliminate malabsorption. Some other delivery routes (injections, suppositories, sprays, and sublingual and transdermal administrations) are aimed at circumventing different difficulties in dosing, such as thyroid emergencies and dysphagia. Moreover, nanomaterials have been used to develop delivery systems for the sustained release of levothyroxine to improve patient compliance and reduce costs. Some delivery systems encapsulating nanoparticles show promising release profiles. In this review, we first summarize the medical conditions that interfere with the bioavailability of oral levothyroxine and discuss the underlying mechanisms and treatments. The efficacy of liquid solutions and soft gel capsules are systematically evaluated. We further summarize the novel delivery routes for levothyroxine and their possible applications. Nanomaterials in the levothyroxine field are then discussed and compared based on their load and release profile. We hope the article provides novel insights into the drug delivery of levothyroxine.

22 April 2026 in Acta Pharmaceutica Sinica B
Verified
Journal Article
Open access
WZWen Zhang
Wen Zhang
HLHanqing Liu
Hanqing Liu
JHJinxuan Hou
Jinxuan Hou
KLKai Lei
Kai Lei
JLJiapeng Lei
Jiapeng Lei
WLWei Li
Wei Li

28 October 2026 in Advanced Science
Verified
Journal Article
Open access
PDF file
YZYongnian Zeng
Yongnian Zeng
ZCZhigang Chu
Zhigang Chu
HYHuiyuan Yang
Huiyuan Yang
WZWen Zhang
Wen Zhang
PJPeng Jiang
Peng Jiang
WLWei Li
Wei Li
Burn wounds complicated by bacterial infection and fibrotic scarring remain a major clinical challenge, demanding therapeutics capable of coordinated infection control, inflammation modulation, and tissue regeneration. Here, we report a phase‐programmed microneedle (MN) patch (QR/AB‐MNs) that enables spatiotemporally controlled release of ammonia borane (AB) and quercetin (QR) to achieve synergistic antimicrobial and anti‐fibrotic therapy. The MNs comprise a poly (lactic‐co‐glycolic acid) (PLGA) shell encapsulating QR and a sulfobutylether‐β‐cyclodextrin (SBECD) core loaded with the H 2 ‐releasing prodrug AB. Upon exposure to the mildly acidic wound microenvironment, the system triggers sustained generation of hydrogen (H 2 ) and AB degradation products, effectively eliminating bacteria and biofilms while mitigating oxidative stress. Subsequently, gradual PLGA degradation ensures prolonged QR release, suppressing fibroblast hyperproliferation and TGF‐ β mediated collagen deposition, thereby preventing hypertrophic scarring. In murine and rabbit burn models, QR/AB‐MNs markedly accelerated wound closure, reduced inflammation and bacterial burden, restored skin appendages, and yielded scar‐reduced regeneration with native‐like collagen architecture. Transcriptomic profiling further revealed that QR/AB‐MNs orchestrate a broad anti‐fibrotic transcriptional program, concurrently attenuating pro‐fibrotic signaling, cell‐extracellular matrix interactions, and collagen synthesis. Collectively, this programmable MN platform integrates redox modulation, anti‐infective therapy, and matrix remodeling to achieve comprehensive, scarless‐like healing of infected burn wounds.